Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate

Dong Yun Lee, Sang Kyoon Kim, Yoo Shin Kim, Dai Hyun Son, Jong Hee Nam, In-San Kim, Rang Woon Park, Sang Yoon Kim, Youngro Byun

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Heparin, a potent inhibitor of blood coagulation, exhibits antitumoral action in tumor progression such as in angiogenesis and metastasis but is not orally absorbed in the body, making it an attractive candidate as an oral drug for antiangiogenic cancer therapy. We generated LHD or orally active heparin using low molecular weight heparin (LMWH) and deoxycholic acid that is effectively absorbed in the gastrointestinal tract. Using the in vitro endothelial tubular formation and chicken chorioallantoic membrane angiogenesis assay, we found that antiangiogenic activity of this LHD was similar to that of LMWH. From the in vivo Matrigel plugs assay, LHD treated orally could effectively inhibit angiogenesis into the plugs induced by basic fibroblast growth factor, whereas LMWH treated orally could not due to no oral absorption. In addition, when this LHD was orally administered into the tumor bearing mice, it significantly inhibited tumor growth by its antiangiogenic therapeutic mechanism, and when accompanied with doxorubicin, it appeared to have an additive effect. Collectively, LHD having antiangiogenic activity could be orally absorbable and inhibit tumor growth via inhibiting angiogenesis. These findings demonstrate the therapeutic potential of LHD in the clinical trials, which is suggested as a new oral therapeutic remedy for cancer therapy.

Original languageEnglish
Pages (from-to)310-317
Number of pages8
JournalJournal of Controlled Release
Volume118
Issue number3
DOIs
Publication statusPublished - 2007 Apr 23
Externally publishedYes

Fingerprint

Deoxycholic Acid
Heparin
Low Molecular Weight Heparin
Growth
Neoplasms
Therapeutics
Chorioallantoic Membrane
Blood Coagulation
Fibroblast Growth Factor 2
Doxorubicin
Gastrointestinal Tract
Chickens
Clinical Trials
Neoplasm Metastasis
Pharmaceutical Preparations

Keywords

  • Angiogenesis
  • Chemotherapy
  • Deoxycholic acid
  • Drug delivery
  • Growth factor
  • Heparin

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate. / Lee, Dong Yun; Kim, Sang Kyoon; Kim, Yoo Shin; Son, Dai Hyun; Nam, Jong Hee; Kim, In-San; Park, Rang Woon; Kim, Sang Yoon; Byun, Youngro.

In: Journal of Controlled Release, Vol. 118, No. 3, 23.04.2007, p. 310-317.

Research output: Contribution to journalArticle

Lee, Dong Yun ; Kim, Sang Kyoon ; Kim, Yoo Shin ; Son, Dai Hyun ; Nam, Jong Hee ; Kim, In-San ; Park, Rang Woon ; Kim, Sang Yoon ; Byun, Youngro. / Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate. In: Journal of Controlled Release. 2007 ; Vol. 118, No. 3. pp. 310-317.
@article{6ed15bfb20fd48a89fdcaeb35e87d4ac,
title = "Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate",
abstract = "Heparin, a potent inhibitor of blood coagulation, exhibits antitumoral action in tumor progression such as in angiogenesis and metastasis but is not orally absorbed in the body, making it an attractive candidate as an oral drug for antiangiogenic cancer therapy. We generated LHD or orally active heparin using low molecular weight heparin (LMWH) and deoxycholic acid that is effectively absorbed in the gastrointestinal tract. Using the in vitro endothelial tubular formation and chicken chorioallantoic membrane angiogenesis assay, we found that antiangiogenic activity of this LHD was similar to that of LMWH. From the in vivo Matrigel plugs assay, LHD treated orally could effectively inhibit angiogenesis into the plugs induced by basic fibroblast growth factor, whereas LMWH treated orally could not due to no oral absorption. In addition, when this LHD was orally administered into the tumor bearing mice, it significantly inhibited tumor growth by its antiangiogenic therapeutic mechanism, and when accompanied with doxorubicin, it appeared to have an additive effect. Collectively, LHD having antiangiogenic activity could be orally absorbable and inhibit tumor growth via inhibiting angiogenesis. These findings demonstrate the therapeutic potential of LHD in the clinical trials, which is suggested as a new oral therapeutic remedy for cancer therapy.",
keywords = "Angiogenesis, Chemotherapy, Deoxycholic acid, Drug delivery, Growth factor, Heparin",
author = "Lee, {Dong Yun} and Kim, {Sang Kyoon} and Kim, {Yoo Shin} and Son, {Dai Hyun} and Nam, {Jong Hee} and In-San Kim and Park, {Rang Woon} and Kim, {Sang Yoon} and Youngro Byun",
year = "2007",
month = "4",
day = "23",
doi = "10.1016/j.jconrel.2006.12.031",
language = "English",
volume = "118",
pages = "310--317",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate

AU - Lee, Dong Yun

AU - Kim, Sang Kyoon

AU - Kim, Yoo Shin

AU - Son, Dai Hyun

AU - Nam, Jong Hee

AU - Kim, In-San

AU - Park, Rang Woon

AU - Kim, Sang Yoon

AU - Byun, Youngro

PY - 2007/4/23

Y1 - 2007/4/23

N2 - Heparin, a potent inhibitor of blood coagulation, exhibits antitumoral action in tumor progression such as in angiogenesis and metastasis but is not orally absorbed in the body, making it an attractive candidate as an oral drug for antiangiogenic cancer therapy. We generated LHD or orally active heparin using low molecular weight heparin (LMWH) and deoxycholic acid that is effectively absorbed in the gastrointestinal tract. Using the in vitro endothelial tubular formation and chicken chorioallantoic membrane angiogenesis assay, we found that antiangiogenic activity of this LHD was similar to that of LMWH. From the in vivo Matrigel plugs assay, LHD treated orally could effectively inhibit angiogenesis into the plugs induced by basic fibroblast growth factor, whereas LMWH treated orally could not due to no oral absorption. In addition, when this LHD was orally administered into the tumor bearing mice, it significantly inhibited tumor growth by its antiangiogenic therapeutic mechanism, and when accompanied with doxorubicin, it appeared to have an additive effect. Collectively, LHD having antiangiogenic activity could be orally absorbable and inhibit tumor growth via inhibiting angiogenesis. These findings demonstrate the therapeutic potential of LHD in the clinical trials, which is suggested as a new oral therapeutic remedy for cancer therapy.

AB - Heparin, a potent inhibitor of blood coagulation, exhibits antitumoral action in tumor progression such as in angiogenesis and metastasis but is not orally absorbed in the body, making it an attractive candidate as an oral drug for antiangiogenic cancer therapy. We generated LHD or orally active heparin using low molecular weight heparin (LMWH) and deoxycholic acid that is effectively absorbed in the gastrointestinal tract. Using the in vitro endothelial tubular formation and chicken chorioallantoic membrane angiogenesis assay, we found that antiangiogenic activity of this LHD was similar to that of LMWH. From the in vivo Matrigel plugs assay, LHD treated orally could effectively inhibit angiogenesis into the plugs induced by basic fibroblast growth factor, whereas LMWH treated orally could not due to no oral absorption. In addition, when this LHD was orally administered into the tumor bearing mice, it significantly inhibited tumor growth by its antiangiogenic therapeutic mechanism, and when accompanied with doxorubicin, it appeared to have an additive effect. Collectively, LHD having antiangiogenic activity could be orally absorbable and inhibit tumor growth via inhibiting angiogenesis. These findings demonstrate the therapeutic potential of LHD in the clinical trials, which is suggested as a new oral therapeutic remedy for cancer therapy.

KW - Angiogenesis

KW - Chemotherapy

KW - Deoxycholic acid

KW - Drug delivery

KW - Growth factor

KW - Heparin

UR - http://www.scopus.com/inward/record.url?scp=33947323758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947323758&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2006.12.031

DO - 10.1016/j.jconrel.2006.12.031

M3 - Article

VL - 118

SP - 310

EP - 317

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -